CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.374
AS - Asia 25.263
EU - Europa 18.811
SA - Sud America 2.120
AF - Africa 1.231
OC - Oceania 62
Continente sconosciuto - Info sul continente non disponibili 22
Totale 73.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.070
SG - Singapore 7.842
CN - Cina 7.790
GB - Regno Unito 4.423
VN - Vietnam 4.114
IT - Italia 3.034
DE - Germania 2.845
SE - Svezia 2.248
HK - Hong Kong 1.945
BR - Brasile 1.579
IN - India 1.283
NL - Olanda 1.221
RU - Federazione Russa 1.167
KR - Corea 1.117
UA - Ucraina 788
FR - Francia 736
IE - Irlanda 683
ZA - Sudafrica 403
JP - Giappone 347
FI - Finlandia 341
CI - Costa d'Avorio 312
EE - Estonia 309
AR - Argentina 249
TG - Togo 203
ID - Indonesia 192
CH - Svizzera 179
AT - Austria 157
CA - Canada 156
JO - Giordania 135
HR - Croazia 127
SC - Seychelles 120
PL - Polonia 114
MX - Messico 101
BG - Bulgaria 91
EC - Ecuador 89
BE - Belgio 79
NG - Nigeria 78
ES - Italia 68
BD - Bangladesh 65
IR - Iran 57
CL - Cile 51
AU - Australia 47
TR - Turchia 47
CO - Colombia 45
GR - Grecia 43
IQ - Iraq 40
PY - Paraguay 36
LB - Libano 33
EG - Egitto 30
PK - Pakistan 27
VE - Venezuela 26
LT - Lituania 25
PE - Perù 25
UZ - Uzbekistan 25
LU - Lussemburgo 21
RO - Romania 20
CZ - Repubblica Ceca 19
IL - Israele 19
MY - Malesia 19
SA - Arabia Saudita 19
AE - Emirati Arabi Uniti 18
EU - Europa 18
PH - Filippine 18
TN - Tunisia 18
MA - Marocco 17
TW - Taiwan 16
KZ - Kazakistan 14
DK - Danimarca 13
DZ - Algeria 13
UY - Uruguay 13
DO - Repubblica Dominicana 12
AL - Albania 11
NZ - Nuova Zelanda 11
AZ - Azerbaigian 10
RS - Serbia 10
TH - Thailandia 10
PA - Panama 8
BO - Bolivia 7
KE - Kenya 7
NP - Nepal 7
BH - Bahrain 6
CR - Costa Rica 6
PT - Portogallo 6
AM - Armenia 5
GT - Guatemala 5
HU - Ungheria 5
QA - Qatar 5
UG - Uganda 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
KG - Kirghizistan 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
MK - Macedonia 4
OM - Oman 4
PR - Porto Rico 4
AO - Angola 3
BN - Brunei Darussalam 3
ET - Etiopia 3
Totale 73.813
Salva come PNG Salva come JPEG
Città #
Singapore 5.144
Southend 3.817
Fairfield 3.121
Ashburn 2.676
Hefei 2.536
Hong Kong 1.921
Chandler 1.648
Woodbridge 1.504
Houston 1.469
Seattle 1.375
Wilmington 1.365
Cambridge 1.106
Princeton 1.089
Seoul 1.082
Ann Arbor 1.038
Santa Clara 979
Ho Chi Minh City 848
Boardman 795
Dong Ket 762
Beijing 759
Dublin 683
Kerkrade 666
Hanoi 615
Bologna 574
Frankfurt am Main 449
Los Angeles 426
Nanjing 417
Jacksonville 415
Westminster 412
Padova 337
Berlin 336
Milan 315
Tokyo 315
Abidjan 312
Dallas 287
New York 283
Buffalo 272
Bengaluru 232
Jinan 231
Redondo Beach 211
Helsinki 208
Lomé 202
San Diego 194
Saint Petersburg 192
Shenyang 188
Changsha 158
São Paulo 158
Nuremberg 138
Turin 137
Amman 134
Hebei 134
Guangzhou 128
Bern 127
Nanchang 127
Tianjin 120
Bremen 119
Jakarta 119
Munich 117
Zhengzhou 115
Rome 111
London 107
Lappeenranta 102
Chicago 98
Shanghai 95
Mülheim 94
Redmond 93
Redwood City 93
Hangzhou 89
Jiaxing 89
Des Moines 84
Haiphong 84
Sofia 84
Falls Church 80
Olalla 78
Dearborn 76
Hyderabad 75
Yubileyny 75
Warsaw 74
Falkenstein 72
Vienna 70
Florence 69
Norwalk 68
Phoenix 68
Taizhou 68
Brussels 66
Abeokuta 65
Tongling 65
Da Nang 64
Toronto 63
Rio de Janeiro 61
Biên Hòa 59
Ningbo 56
Amsterdam 52
Verona 52
Secaucus 50
Haikou 49
Taiyuan 49
Mahé 47
Düsseldorf 46
Brooklyn 44
Totale 48.621
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 1.449
Consensus conference on the management of tumor lysis syndrome. 392
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 380
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. 354
18F-FDG PET early after radiotherapy in lymphoma patients. 292
Biology and treatment of follicular lymphoma. 264
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 261
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 254
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 248
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 247
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 241
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 241
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 237
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 233
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 227
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 226
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 226
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 221
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 216
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 216
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 216
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 211
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 208
18 F-FDG PET in malignant lymphoma: significance of positive findings 208
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 207
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 205
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 202
T-Cell Lymphomas in South America and Europe 202
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 200
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 200
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 197
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 196
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 195
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 195
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 192
Expression of CD52 in peripheral T-cell lymphoma. 192
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 190
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 189
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 187
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 187
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 185
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 184
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 184
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 183
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 183
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 183
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 182
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
Detection of Brain-Derived Cell-Free DNA in Plasma 181
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 181
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 181
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 180
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 180
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. 180
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 179
RALE051: a novel established cell line of sporadic Burkitt lymphoma 179
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 176
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 175
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 175
Histopathology of B-cell chronic lymphocytic leukemia. 174
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 174
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 173
The role of mitoxantrone in the treatment of indolent lymphomas. 172
CD30 expression in peripheral T-cell lymphomas 172
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 172
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 172
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 171
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 170
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 170
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 169
A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. 169
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
Utility of baseline 18FDG PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 169
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 168
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 168
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 168
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 167
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. 166
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 166
Anaplastic Large Cell Lymphoma: a critical reappraisal 165
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 165
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 165
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 164
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 164
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 164
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 163
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 163
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 163
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 162
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials 161
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. 160
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 159
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 159
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 158
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 156
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 156
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 155
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 155
Totale 20.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.990
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.051 0 0 0 0 0 429 81 325 673 278 317 1.948
2021/20228.269 901 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.799 180 449 201 270 223 374 177 180 98 278 218 151
2024/202514.004 430 2.120 1.121 963 1.794 681 1.165 392 347 1.025 1.003 2.963
2025/202620.030 3.055 4.480 3.615 2.872 3.298 2.710 0 0 0 0 0 0
Totale 75.511